by Garth Sundem | Jun 27, 2019 | Latest News, Research
Sameer Nath, MD When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better. So why did a large phase 3 clinical trial find exactly the opposite – that stage III non-small cell lung cancer patients treated with...
by Garth Sundem | May 30, 2019 | Featured, Research
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib, alectinib, and brigatinib have earned FDA approval as second-line therapies after treatment...
by Garth Sundem | May 21, 2019 | Featured, Latest News, Patient Care
D. Ross Camidge, MD, PhD Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published in the New England...
by Garth Sundem | Mar 28, 2019 | Latest News, Research
Robert C. Doebele, MD, PhD A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion...
by Garth Sundem | Mar 6, 2019 | Featured, Honors, Latest News
James DeGregori, PhD The American Association for Cancer Research (AACR) announced today that in partnership with the Lung Cancer Initiative at Johnson & Johnson, it will fund a major grant led by University of Colorado Cancer Center investigators to pinpoint the...
